Changing the Paradigm (ASX:PAR): Revolutionising osteoarthritis management

The Unicorns Podcast connects you to some of the best and brightest founders, CEOs, executives, business owners, innovators, entrepreneurs and inspiring leaders who make things happen and inspire others.
Host Justin Kelly, former broadcast journalist and PR veteran, chats with leaders from across Australia and internationally on business strategy; what it takes to build a successful company; how to overcome challenges, and advice for those on a similar journey.

In this episode, Justin talks with Paul Rennie, CEO of late-stage drug development company Paradigm Biopharmaceutics (ASX:PAR).

Paradigm’s immediate commercial focus is the development of injectable Pentosan Polysulfate Sodium (iPPS) for the treatment of osteoarthritis. This is a global unmet need and Paradigm has advanced to Phase 3 trials in the space. Addressing all aspect of the disease; inflammation, pain and regeneration, iPPS has genuine disease modifying potential.

The post Changing the Paradigm (ASX:PAR): Revolutionising osteoarthritis management appeared first on Stockhead.